We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function due to damage to the peripheral nerves. Symptoms may include numbness, tingling, and muscle weakness.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.